标题
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
作者
关键词
-
出版物
NATURE
Volume 601, Issue 7894, Pages 617-622
出版商
Springer Science and Business Media LLC
发表日期
2021-11-24
DOI
10.1038/s41586-021-04232-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
- (2021) Anthony T. Tan et al. Cell Reports
- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
- (2021) Houriiyah Tegally et al. NATURE
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- (2021) Zijun Wang et al. NATURE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
- (2021) Leticia Monin et al. LANCET ONCOLOGY
- A vaccine targeting mutant IDH1 in newly diagnosed glioma
- (2021) Michael Platten et al. NATURE
- Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
- (2021) Nuno R. Faria et al. SCIENCE
- T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
- (2021) Tatjana Bilich et al. Science Translational Medicine
- Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups
- (2021) Hans-Georg Rammensee et al. Vaccines
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- (2021) Xinxue Liu et al. LANCET
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
- (2020) Lennard Y W Lee et al. LANCET
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
- (2020) Annarosa Soresina et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
- (2020) Julian Braun et al. NATURE
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
- (2020) Nina Le Bert et al. NATURE
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
- (2020) Jose Mateus et al. SCIENCE
- SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
- (2020) Annika Nelde et al. NATURE IMMUNOLOGY
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
- (2020) Lauren B. Rodda et al. CELL
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
- (2019) Hans-Georg Rammensee et al. Journal for ImmunoTherapy of Cancer
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review
- (2015) Eva van Doorn et al. Human Vaccines & Immunotherapeutics
- Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine
- (2012) Jacob Atsmon et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer
- (2009) Susan Feyerabend et al. PROSTATE
- Cytotoxic human CD4+ T cells
- (2008) Pablo J van de Berg et al. CURRENT OPINION IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started